Is Autologous Bone Marrow Transplant (Abmt) and High-Dose Chemotherapy an Approach That Can Rescue Some Children With Advanced Cancer Disease?

Rivera-Luna, Roberto; Olaya-Vargas, Alberto; Meza-Coria, C.; Cárdenas-Cardós, Rocío; Leal-Leal, Carlos; Amador-Zarco, Jorge

doi:10.1080/088800101750476023

Cited by 2 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a previous work by our group of 15 consecutive children with advanced cancer submitted to three different myeloablative chemotherapy regimens and AHPSCT, the OS was 40% and the mean DFS was 19 months ( 6 ) . However the current study shows that single chemotherapy regimens can give more standardized results.…”

Section: Discussionmentioning

confidence: 90%

“…Therefore, increases in chemotherapy of 3 to 10 times denote multiple-logarithmic increases in the destruction of malignant cells. However, the main limit of this principle is the extended myelotoxicity which puts the patient's life at risk ( 2 - 6 ) .…”

Section: Introductionmentioning

confidence: 99%

“…The aim of the current study was to evaluate the efficacy and safety of a myeloablative chemotherapy program without TBI using melphalan, cyclophosphamide and etoposide followed by consolidation-rescue with autologous hematopoietic progenitor stem cell transplantation (AHPSCT) as treatment for high-risk solid tumors in children. All these drugs, with demonstrated efficacy, are available in Mexico ( 6 ) .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Consolidation treatment for high risk solid tumors in children with myeloablative chemotherapy and autologous hematopoietic progenitor stem cell transplantation

Olaya-Vargas¹,

Luna

García

et al. 2013

Revista Brasileira De Hematologia E Hemoterapia

View full text Add to dashboard Cite

BackgroundIn childhood cancer, consolidation treatment with chemotherapy followed by autologous hematopoietic progenitor stem cell transplantation is currently an accepted treatment modality in patients with high-risk solid tumors or in patients who have relapsed after conventional treatment. ObjectivesThe objective of this study was to describe the results of transplantation of a group of children who had high-risk solid tumors or relapsed after conventional chemotherapy regimens. MethodsA retrospective analysis was conducted from January 1998 to October 2004 of all children with pathologic diagnoses of high-risk solid tumors or children that had previously relapsed after conventional chemotherapy and that were subsequently submitted to autologous hematopoietic progenitor stem cell transplantation. The analysis included overall survival rates, event-free survival rates, mortality rates and chemotherapy complications. ResultsNineteen patients were submitted to this approach. The age range was from 27 to 196 months with a median age of 52 months. The overall survival rate at 100 days was observed in 79%, the three-year event-free survival rate was 63%. The mortality rate secondary to the myeloablative chemotherapy regimen was 21% (n = 4). Only three patients (15.8%) relapsed with tumor progression after transplant. ConclusionAutologous hematopoietic progenitor stem cell transplantation is still a successful procedure in patients with solid tumors refractory to conventional chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 90%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation